SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
前日終値
$20.10
+$0.73 · +3.77%
時間外
$20.14
+$0.04 · +0.20%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
日中レンジ
現在 $20.10
52週レンジ
現在 $20.10
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
99
大幅な割安
センチメント
49
まちまち
リスク
38
中程度のリスク
モメンタム
58
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
日中レンジ
現在 $20.10
52週レンジ
現在 $20.10
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.01億 USD | 1.67億 USD | 1.39億 USD | 1.06億 USD | 9015.2万 USD |
| 売上原価 | 4104.7万 USD | 3505.7万 USD | 2946.6万 USD | 1570.5万 USD | 1042.8万 USD |
| 粗利益 | 1.6億 USD | 1.32億 USD | 1.09億 USD | 9070.4万 USD | 7972.4万 USD |
| 研究開発 | 1744.8万 USD | 1656万 USD | 1502.8万 USD | 1362.7万 USD | 1244.1万 USD |
| 販売・一般管理 | 1.65億 USD | 1.51億 USD | 1.41億 USD | 1.37億 USD | 1.19億 USD |
| 営業費用 | 1.82億 USD | 1.67億 USD | 1.56億 USD | 1.5億 USD | 1.31億 USD |
| 受取利息 | 607.3万 USD | 784.8万 USD | 691.6万 USD | 130.4万 USD | 18.6万 USD |
| 支払利息 | 528.3万 USD | 344万 USD | 346.2万 USD | 281.9万 USD | 536.5万 USD |
| 減価償却費と償却費 | 271.9万 USD | 437.9万 USD | 542.8万 USD | 345.2万 USD | 208.6万 USD |
| 営業利益 | −2233万 USD | −3524.8万 USD | −4693.1万 USD | −5960.9万 USD | −5167万 USD |
| 純利益 | −1890.8万 USD | −3091.3万 USD | −4333.6万 USD | −6125.6万 USD | −5657.2万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2543.07万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM2220.25万0.03%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF881.19万0.01%954億 USD0.05%$233.52-0.63%
iShares Russell 2000 Growth ETFIWO780.88万0.06%139.17億 USD0.24%$353.71-0.86%
Dimensional - US Small Cap ETFDFAS542.41万0.02%338.69億 USD0.31%$78.17-0.23%
Vanguard Russell 2000 ETFVTWO480.57万0.03%180億 USD0.06%$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA464.27万0.02%218.24億 USD0.03%$32.66-0.40%
iShares U.S. Medical Devices ETFIHI429.82万0.12%35.74億 USD0.37%$52.79+2.03%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
iShares U.S. Medical Devices ETFIHIAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。